The UK regulatory framework distinguishes between clinical trials of investigational medicinal products (CTIMPs) and studies that don't involve testing medicines in that experimental sense. Non-CTIMP studies — covering observational designs, dietary interventions, real-world data collection, and many nutritional studies — operate under a different, often more proportionate set of requirements. Yet many sponsors default to CTIMP-level processes even when their study doesn't warrant them, driving unnecessary cost and complexity.
Understanding where the boundary lies, and what non-CTIMP status actually enables, is one of the most valuable things a sponsor can do before a study begins.
What makes a study non-CTIMP?
A study is a CTIMP if it is a clinical trial involving an investigational medicinal product — broadly, a substance being tested or used in an experimental context for its pharmacological, immunological, or metabolic properties. This is a meaningful distinction. Many studies involving food, dietary supplements, nutrition, behavioural interventions, or simply the collection of real-world data do not meet this definition.
Non-CTIMP studies still require ethical oversight — they need Research Ethics Committee (REC) approval and must comply with Good Clinical Practice (GCP) principles proportionate to their risk level. But they operate without the additional regulatory layer that applies to CTIMPs, including Clinical Trial Authorisation from the MHRA.
This isn't a regulatory loophole. It's the framework working as intended: regulation proportionate to risk.
Worth knowing: the CTIMP/non-CTIMP boundary turns on whether the study is testing an investigational medicinal product for its pharmacological, immunological, or metabolic effect — not on how the intervention is delivered, how many participants are involved, or how long the study runs. A large, long-running dietary cohort study is still non-CTIMP; a small trial of a repurposed drug is still a CTIMP.
The scientific case for proportionate governance
There is a widespread assumption in clinical research that more regulation equals better science. In practice, the relationship is more nuanced. Over-regulating low-risk studies creates real problems:
- Inflated budgets diverted to compliance rather than data quality
- Longer set-up timelines that delay answers and discourage participation
- Regulatory burden on sites that discourages institutions from participating in lower-risk research
- Study designs shaped by compliance constraints rather than scientific questions
When a nutritional study is designed and governed as though it carries the same risk profile as a complex interventional trial, the overhead can become so significant that the study simply isn't feasible. The result is a gap in the evidence base — not better safety.
Non-CTIMP governance, properly applied, focuses resources on what matters: robust participant consent, sound data collection, meaningful ethical oversight, and high-quality analysis. It removes friction without removing rigour.
Where non-CTIMP studies generate real value
Some of the most important questions in nutrition and public health are best answered through non-CTIMP designs. These include:
- Dietary pattern studies examining how food intake relates to health outcomes across populations
- Observational cohort studies tracking outcomes in real-world settings without experimental intervention
- Nutritional supplementation studies involving products regulated as foods rather than medicines
- Real-world evidence studies using patient-reported outcomes, diaries, or wearable-generated data to understand behaviour and health
- Post-market surveillance for food and health products generating evidence for regulatory submissions and health claims
In each of these cases, the study question, the participant population, and the nature of the intervention align naturally with non-CTIMP governance. Applying CTIMP processes adds cost and complexity without proportionate scientific or safety benefit.
A live example
This isn't an abstract distinction. London South Bank University's exploratory pilot study on retail-available fermented foods — examining effects on cognition, mood, and the gut microbiome — is registered on ISRCTN with ethics approval already in place, and sits comfortably within non-CTIMP governance: participants consume food products already available to buy, not an investigational medicine. A study asking the same broad question — does a dietary pattern affect cognitive or mood outcomes — but built around a novel pharmacological compound would sit in a completely different regulatory category, with a correspondingly different cost and timeline. The intervention type, not the ambition of the research question, is what determines the pathway.
The reform is moving the same direction
The case for proportionate governance isn't just a design philosophy — it's the direction UK clinical research regulation is actively moving in. The Health Research Authority's reform of the clinical trials regulations, and the MHRA Inspectorate's own communications tracking it, have repeatedly emphasised a shift toward risk-proportionate, streamlined pathways rather than a single uniform process applied regardless of risk. The Inspectorate's own "Route B" pilot for substantial modifications was explicitly framed around letting lower-risk changes move through a lighter process than higher-risk ones — the same underlying logic that already separates CTIMP from non-CTIMP governance, just applied one level down, inside CTIMP trials themselves.
For sponsors, the practical takeaway is that proportionate regulation isn't a workaround to be justified defensively — it's the framework's own stated direction of travel. Designing a study around the governance level it actually needs, rather than defaulting upward "to be safe," is increasingly the position regulators themselves are pushing toward, not a departure from it.
Getting the classification right from the start
Classification matters most at the design stage. Getting it wrong — whether by applying CTIMP processes to a study that doesn't need them, or by inadvertently failing to seek the right approvals — has consequences for timelines, costs, and data credibility.
The key questions to work through are:
- Does the study involve a medicinal product as defined in UK legislation?
- What is the primary purpose of the study — testing an intervention, or observing real-world outcomes?
- What is the risk profile for participants?
- What ethics and governance bodies need to be involved?
These questions are best answered early, ideally at the protocol development stage, with input from people who understand both the regulatory framework and the scientific intent.
The broader opportunity
Non-CTIMP research is not a second-class category. Some of the most influential evidence in nutrition and public health — large observational cohorts, dietary intervention studies, real-world outcome registries — has been generated outside CTIMP frameworks. As demand for robust real-world evidence grows from regulators, payers, and commissioners alike, the ability to design and deliver high-quality non-CTIMP studies efficiently becomes a genuine strategic advantage.
Working within proportionate governance frameworks is not a compromise. It's how you design studies that are feasible, rigorous, and capable of generating evidence that actually gets used.